Answers are grounded in this paper and cite their sources.
Low C-peptide levels in type 2 diabetes mellitus patients indicate reduced insulin secretion capacity and influence treatment decisions, leaning towards strategies common in type 1 diabetes like automated insulin delivery. Further research is needed to directly address treatment efficacy in low C-peptide T2DM populations.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: